Early Surgery for Mild DCM – Is it Cost-Effective?

Degenerative Cervical Myelopathy (DCM) can be highly debilitating and is becoming more prevalent. Evidence is accumulating regarding treatment of DCM but since healthcare demand is outstripping supply, value-based decisions must be made about what, where, when and to whom resources are allocated. As such, it is paramount to understand the conditions under which treatment for DCM is cost-effective. 

Surgical treatment of moderate or severe DCM is cost-effective, but whether this extends to mild DCM is unclear. Since the role for early surgery in mild DCM is controversial, its cost-effectiveness can make or break further evaluation and utilisation. The study by Malhotra et al. sought to answer whether early surgery for DCM is cost-effective.   

How was this study conducted?

Malhota et al. performed cost-utility analysis of early surgery versus observation for mild DCM. They drew data from the prospective cohort of patients in the Cervical Spondylotic Myelopathy AO and North America Studies from 2005 – 2011. There are four relevant parts to the methodology:

Costs were determined from the healthcare system perspective

Costs, such as staffing and operating theatre costs, were extracted from previously published studies. This perspective of costing is appropriate for a cost-utility analysis and does not detract from the conclusions. However, there is a significant amount of information to be gleaned about costs to the patient (e.g., travel costs, medication costs) and society (e.g., loss of productivity) that are not considered in this perspective.  

Utilities were determined using SF-6D

A cost-utility analysis must have an estimate of health-related quality-of-life (HRQoL), which was determined using the short form (SF)-6D at baseline and 6, 12 and 24 months post-operatively. This is an appropriate tool to use for a cost-utility analysis, and the answers about a variety of domains (e.g., physical functioning, pain) are transformed into an associated health state with an associated HRQoL on a scale of 0 – 1. This is a controversial area, with some arguing that the HRQoL should be directly reported by the individual with the condition rather than from a population decision. 

Costs and utilities were estimated throughout the lifespan

DCM is a chronic condition, and estimating costs and utilities throughout the lifespan is an appropriate and robust methodology that offers improvements over previous research. They achieve this with mathematical modelling, an accepted technique in the economic evaluations. This also allowed the authors to calculate quality-adjusted life years (QALYs), which are a product of HRQoL and number of years lived in a given health state. For example, one QALY is one year lived with perfect health. Alternatively, 10 years lived with a HRQoL of 0.5 would represent five QALYs. 

Cost-effectiveness was estimated with the incremental cost-utility ratio

The authors take the costs and utilities and calculate an incremental cost-utility ratio (ICUR). Effectively, this tells us how much extra we must pay to receive an additional QALY. For decision makers to consider funding a treatment, the ICUR must be less than a willingness-to-pay (WTP) threshold, which varies from country to country – for example, ~ £20,000 in the UK and ~ $50,000 in the US. 

What was discovered?

The study had three important findings: 

On average, mild DCM has better HRQoL than moderate or severe DCM, but there is significant variation

The authors found that the overall mean pre-operative HRQoL was higher in mild DCM than moderate or severe DCM. However, the range of HRQoL showed significant overlap. In other words, individual patients with any severity of DCM can have a HRQoL that ranges from excellent to very poor. 

Early surgery meaningfully improves HRQoL in mild DCM

The authors found that the average improvement in HRQoL at 12 months after early surgery for mild DCM was almost four times the accepted minimum clinically important difference. Although it remains unclear how HRQoL changes over a longer time period, this study adds additional evidence in favour of early surgery for mild DCM. 

Early surgery for mild DCM is cost-effective in 100% of cases

The authors found that the ICUR for early surgery was approximately $10,000/QALY. This means that surgery costs an additional $10,000 to achieve an additional year of life lived in good health. This is well below the Canadian WTP threshold (~ $50,000/QALY) and accounting for exchange rates and inflation, is still below the UK WTP threshold (~ £20,000/QALY). However, baseline HRQoL can have a profound impact on cost-effectiveness yet further modelling demonstrated that early surgery for DCM is cost-effective in 100% of cases, regardless of the baseline HRQoL. 

Why is this important? 

The work of Malhotra et al. is important for three reasons. Firstly, it confirm the heterogeneity of DCM and the disconnect between disease severity and symptomatology. This is an essential area of further research to better understand mechanistic explanations and predictors of outcomes.

Secondly, it added further evidence that early surgery for mild DCM, at least in the short-term, improves HRQoL.

Finally, it demonstrated that early surgery for mild DCM is cost-effective in all cases, which facilitates further research and expansion of early decompressive surgery. However, it will be important that this work is replicated in different countries, where the healthcare economics are different as well as with more modern datasets.

Moreover, it highlights the need to explore other aspects of health economics in DCM, such as the financial impact on patients and loss of productivity from ill health.